论文部分内容阅读
目的 观察预防性应用抗菌药物对重型病毒性肝炎医院感染的影响。方法 选择 1996 - 10～ 2 0 0 1- 12泉州市第一医院入院前 1周未经抗菌治疗、入院时无感染征象、住院时间超过 72h的重型肝炎病例 ,根据临床分期及抗菌药物应用情况进行分组、对照研究。结果 15 9例患者中 76例发生医院感染 ,未预防性应用抗菌药物组 (A组 )、静脉注射第三代头孢菌素组 (B组 )及半合成青霉素组 (C组 )医院感染率分别为 5 6 16 % (41/ 73)、34 0 % (17/ 5 0 )和 5 0 0 % (18/ 36 )。与A组比较 ,B组早、中、晚期重型肝炎医院感染发生时间均明显推迟 ,中期、晚期重型肝炎医院感染发生率明显降低 ,中期重型肝炎病死率明显降低 ,各组差异均有显著性意义。 (P <0 0 5 )。与A组比较 ,C组各期重型肝炎的医院感染发生时间、感染发生率、病死率差异无显著意义 (P >0 0 5 )。结论 预防性应用第三代头孢菌素可推迟重型肝炎医院感染发生时间 ,降低中、晚期重型肝炎医院感染发生率 ,降低中期重型肝炎病死率。
Objective To observe the effect of prophylactic antibiotics on nosocomial infections in patients with severe viral hepatitis. Method selection 1996 - 10 ~ 2 0 0 1-12 Quanzhou No.1 Hospital without antibacterial treatment 1 week before admission, no signs of infection on admission, hospitalization for more than 72h of severe hepatitis, according to the clinical stage and the application of antimicrobial agents Grouping, control study. Results 76 cases of nosocomial infection occurred in 76 out of 15 patients, the rates of nosocomial infection in non-prophylactic antibiotics group (A), third-generation cephalosporin (B group) and semi-synthetic penicillin group (C) Were 56.16% (41/73), 34 0% (17/50) and 500% (18/36). Compared with group A, the incidence of nosocomial infections in early, middle and late stages of severe hepatitis was significantly delayed in group B, the incidence of nosocomial infections in severe and intermediate-stage hepatitis was significantly lower, and the case-fatality rate of mid-term severe hepatitis was significantly lower, with significant differences in each group . (P <0 05). Compared with group A, the incidence of nosocomial infections, the incidence of infection and the case fatality rate in each stage of severe hepatitis in group C were not significantly different (P> 0.05). Conclusion The prophylactic use of the third generation cephalosporins can delay the occurrence of nosocomial infections in severe hepatitis, reduce the incidence of nosocomial infections in severe hepatitis and reduce the mortality of mid-term severe hepatitis.